AV078
Tuberous Sclerosis Complex (TSC) Refractory Epilepsy
Phase 1Active
Key Facts
Indication
Tuberous Sclerosis Complex (TSC) Refractory Epilepsy
Phase
Phase 1
Status
Active
Company
About Aeovian Pharmaceuticals
Aeovian Pharmaceuticals is a private, clinical-stage biotech founded in 2020, pioneering selective mTORC1 inhibition to treat diseases of dysregulated cellular growth. Its lead program, AV078, targets a high-unmet need in TSC-related refractory epilepsy, aiming to overcome the safety limitations of non-selective mTOR inhibitors like everolimus. The company has a broader platform of selective mTORC1 and CD38 inhibitors with potential applications across rare and age-related diseases, backed by an experienced leadership team and venture capital investors.
View full company profile